RJA
ECYT

Raymond James & Associates’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Raymond James & Associates’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-12,900
Closed -$33K – 3481
2017
Q1 		$33K Buy
12,900
+2,000
+18% +$4.63K ﹤0.01% 3174
2016
Q4 		$28K Buy
+10,900
New +$31.3K ﹤0.01% 3130
2015
Q1 		– Sell
-33,791
Closed -$213K – 2432
2014
Q4 		$213K Sell
33,791
-12,721
-27% -$77.5K ﹤0.01% 2208
2014
Q3 		$283K Buy
+46,512
New +$318K ﹤0.01% 2057
2014
Q2 		– Sell
-20,317
Closed -$484K – 2253
2014
Q1 		$484K Buy
+20,317
New +$295K ﹤0.01% 1800

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Raymond James & Associates's ECYT Position: Q2 2017 in Review

Raymond James & Associates sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2017, closing a stake of 12,900 shares — an estimated $33K sold.

Raymond James & Associates first reported a position in ECYT in Q1 2014 and held it in 5 quarters. The position peaked at $484K in Q1 2014. 75 funds tracked by Wall St. Rank hold ECYT as of Q2 2017.

  • Raymond James & Associates reported no remaining Endocyte, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Raymond James & Associates sold 12,900 Endocyte, Inc. Common Stock shares in Q2 2017, an estimated $33K.
  • Raymond James & Associates first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 5 quarters.
  • Raymond James & Associates's Endocyte, Inc. Common Stock position peaked at $484K in Q1 2014.
  • 75 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2017.

Based on Raymond James & Associates's 13F filing for Q2 2017, filed 14 Aug 2017.